Oncept IL-2
feline interleukin-2 recombinant canarypox virus (vCP1338 virus)
Marketing authorisation holder: Boehringer Ingelheim Vetmedica GmbH 55216 Ingelheim/Rhein
GERMANY
Manufacturer responsible for batch release: Boehringer Ingelheim Animal Health France SCS Laboratoire Porte des Alpes
Rue de l'Aviation 69800 Saint Priest France
Oncept IL-2 lyophilisate and solvent for suspension for injection for cats
After reconstitution, each dose of 1 ml contains:
Feline interleukin-2 recombinant canarypox virus (vCP1338) ....................................... ≥ 106.0 EAID*50
*ELISA infectious dose 50%.
Lyophilisate: whitish homogeneous pellet. Solvent: clear colourless liquid.
Immunotherapy to be used in addition to surgery and radiotherapy in cats with fibrosarcoma (2-5 cm diameter) without metastasis or lymph node involvement in order to reduce the risk of relapse and to increase the time to relapse (local recurrence or metastasis). This was demonstrated in a field trial over a period of 2 years.
None.
A moderate local reaction (pain on palpation, swelling, scratching) occurred very commonly in safety studies. It usually disappeared spontaneously within 1 week at most.
Transient apathy and fever (above 39.5 °C) occurred commonly in field studies.
The frequency of adverse reactions is defined using the following convention:
very common (more than 1 in 10 animals treated displaying adverse reaction(s)) during the course of one treatment)
common (more than 1 but less than 10 animals in 100 animals treated)
uncommon (more than 1 but less than 10 animals in 1,000 animals treated )
rare (more than 1 but less than 10 animals in 10,000 animals treated)
very rare (less than 1 animal in 10,000 animals treated, including isolated reports).
If you notice any side effects, even those not already listed in this package leaflet or you think that the medicine has not worked, please inform your veterinary surgeon
Cats.
Subcutaneous use.
After reconstitution of the lyophilisate with the solvent, shake gently and administer five injections (each approximately 0.2 ml) around the tumour excision site: one injection at each corner and one injection at the centre of a 5 cm x 5 cm square centred on the middle of the surgical scar.
Treatment course: 4 administrations at 1-week intervals (day 0, day 7, day 14, day 21) followed by
2 administrations at 2-week intervals (day 35, day 49).
Start the treatment course the day before radiation therapy, preferably within one month after surgical excision.
Not applicable.
Keep out of the sight and reach of children. Store and transport refrigerated (2 °C-8 °C).
Store in the original package in order to protect from light. Do not freeze.
Do not use this veterinary medicinal product after the expiry date which is stated on the label after EXP.
After reconstitution use immediately.
Special warnings for each target species:
Use of the recommended mode of administration in 5 injection points is important for achieving efficacy of the product; injection in 1 point may lead to reduced efficacy (see section “Dosage for each species, route and method of administration”).
Efficacy has only been tested in conjunction with surgery and radiotherapy; therefore the treatment should be conducted according to treatment course described in section “Dosage for each species, route and method of administration”.
Efficacy has not been tested in cats with metastasis or lymph node involvement.
As safety and efficacy of repetition of the treatment to treat fibrosarcoma recurrence have not been investigated, repetition of the treatment should be considered by the veterinarian taking into account the benefit-risk balance.
Efficacy of the treatment has not been investigated beyond 2 years following treatment.
Special precautions to be taken by the person administering the veterinary medicinal product to animals:
Canarypox recombinants are known to be safe for humans. Mild local and/or systemic adverse reactions related to the injection itself may be observed transitorily. Moreover feline IL-2 has been shown to have very low biological activity on human leukocytes compared to human IL-2. In case of accidental self-injection, seek medical advice immediately and show the package leaflet or the label to the physician.
Pregnancy and lactation:
The safety of the veterinary medicinal product has not been established during pregnancy and lactation.
Overdose (symptoms, emergency procedures, antidotes):
After the administration of an overdose (10 doses), transient moderate to marked hyperthermia, as well as local reactions (swelling, redness or slight pain, and in some cases, heat at the injection site) may occur.
Interaction with other medicinal products and other forms of interaction:
No information is available on the safety and efficacy of this immunological veterinary medicinal product when used with any other veterinary medicinal product. A decision to use this immunological veterinary medicinal product before or after any other veterinary medicinal product therefore needs to be made on a case by case basis.
Incompatibilities:
Do not mix with any other veterinary medicinal product, except the solvent supplied for use with the veterinary medicinal product.
Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal product should be disposed of in accordance with local requirements.
The vaccine strain vCP1338 is a recombinant canarypox virus expressing feline interleukin-2 (IL-2). The virus expresses the IL-2 gene at the inoculation site, but does not replicate in the cat.
Oncept IL-2 injected into the tumour bed thus delivers in situ a low dose of feline interleukin-2, which stimulates antitumour immunity while avoiding toxicity associated with systemic treatment.
Specific mechanisms by which immunostimulation induces anti-tumoural activity is not known.
In a randomized clinical study, cats from different origins presenting a fibrosarcoma without metastasis or lymph node involvement were included in two groups, one receiving the reference treatment – surgery and radiotherapy – and the other receiving Oncept IL-2 in addition to surgery and radiotherapy. After two years of study follow-up, Oncept IL-2 treated cats showed a longer median time to relapse (above 730 days) compared to control cats (287 days). Oncept IL-2 treatment reduced the risk of relapse, from 6 months after the start of treatment, by approximately 56% after 1 year and 65% after 2 years, compared to the control group.
Cardboard box containing 6 vials of 1 dose of lyophilisate and 6 vials of 1 ml of solvent.